On Friday, Novo Integrated Sciences Inc NVOS announced it received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (SBLC).
Novo Integrated Sciences is a unique nano-cap company with the potential for massive growth through game-changing, non-dilutive financing. Novo is working towards closing 3 major funding transactions, including a $70M promissory note, $78M for the monetization of gemstones expected to deliver surplus cash, and a one-billion-dollar gold-backed bond. Success in securing funding will be a true inflection point for NVOS, dramatically changing the fortunes of the company for the better.
Novo Integrated Sciences (NASDAQ: NVOS ) stock is rocketing higher on Friday after the company said it wants to further maximize its stock repurchase program. Novo Integrated Sciences' Board of Directors is weighing options for a potential increase to the company's stock repurchase program.
| Health Care Providers & Services Industry | Healthcare Sector | Robert Mattacchione CEO | OTC PINK Exchange | 67011T300 CUSIP |
| US Country | 115 Employees | - Last Dividend | 10 Dec 2020 Last Split | 22 Sep 2017 IPO Date |
Novo Integrated Sciences, Inc., along with its subsidiaries, serves as a multidisciplinary provider of primary care and associated wellness products and services primarily in Canada. Operating in two key segments, Healthcare Services and Product Sales, the company has diversified its offerings to meet a wide range of health needs. Initially known as Turbine Truck Engines, Inc., it transitioned to its current name in July 2017, marking a significant shift towards healthcare. Headquartered in Bellevue, Washington, and functioning as a subsidiary of ALMC-ASAP Holdings, Inc., Novo Integrated Sciences is committed to delivering comprehensive healthcare solutions across various demographics, including pediatric, adult, and geriatric populations.